This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Cramer: The Biotech Revaluation Is On

NEW YORK (Real Money) -- They came right back yesterday. It was as if they didn't skip a beat, aided by the fine results by Johnson & Johnson (JNJ) and Coca-Cola (KO).

It was as if they had a Food and Drug Administration buy program. Of course, the yield hunters went right after stock like Eli Lilly (LLY) and GlaxoSmithKline (GSK) and the now-perennial, 52-week-high AstraZeneca (AZN), the latter totally undeserving of the honor given its poor performance of its actual business as opposed to its stock.

But what I find so astounding isn't the strength in the classic, somewhat high-yielding soft goods stocks but the amazing resilience of the stocksthatgoupeveryday. I am making that one word, because it is the new title I am using for Gilead Sciences (GILD), Biogen Idec (BIIB), Celgene (CELG)) and, perhaps most stunningly, Regeneron Pharmaceuticals (REGN).

Now, each of these companies has some terrific drugs in the works. There are novel formulations and terrific pipelines. That's terrific, but I have to tell you that this everyday revaluation -- one I warned you about when I suggested you buy calls on these stocks -- is pretty stunning.

Editor's Note: This article was originally published on Real Money on April 17. To see Jim Cramer's latest commentary as it's published, sign up for a free trial of Real Money.

Regeneron in particular is most amazing. It has a terrific ophthalmological pipeline as well as the blockbuster Eylea, and it has a potential for a brand-new anti-cholesterol franchise that isn't based on statins, for those who can't tolerate them.

Everyone wants yield because of the scarcity of bonds that give you anywhere near even the reduced yields that Procter & Gamble (PG) and Clorox (CL) give you.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,262.56 +89.32 0.55%
S&P 500 1,842.98 +12.37 0.68%
NASDAQ 4,034.1610 +11.4670 0.29%

Our Tweets

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs